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administration costs and $8,786 in AE costs. The cost per-patient for bortezomib SQ 
was $532,877, including $495,513 in drug costs, $30,906 in administration costs and 
$6,458 in AE costs. The model estimates that 10% of MM patients covered by public 
institutions are using bortezomib IV. If these patients switched to bortezomib SQ, 
total savings to a payer would be $3,803,850 ($120,258/patient, 18.4%), including 
$3,731,088 ($117,958/patient) in administration and $73,626 ($2,328/patient) in AE 
cost savings. ConClusions: The use of bortezomib SQ instead of IV could provide 
access to a highly efficacious therapy while conferring savings to Mexican public 
payers. Given non-inferior efficacy, migration from IV to SQ bortezomib results in 
improved tolerability and reduced administration requirements without reducing 
clinical benefits from treatment.
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objeCtives: Given the recent launch of generic bortezomib IV, payers may look to 
increase utilization of bortezomib IV to contain costs for the treatment of adults with 
relapsed/refractory MM in Venezuela. Prior to the introduction of bortezomib subcu-
taneous (SQ), bortezomib IV was the standard of care. This study evaluates the fiscal 
impact of increased use of generic bortezomib IV on total treatment costs. Methods: 
A budget impact model was developed from the Venezuelan public payer perspective. 
Resource costs were based on local provider interviews (2014 Venezuelan bolivars). 
Treatment dosing and AE rates were based on clinical trials. Inputs for market basket 
comparators, adverse event (AE) management and drug administration were esti-
mated via three clinician interviews. Generic bortezomib IV was assumed to be priced 
at 30% of the price of bortezomib SQ and market adoption was based on manufacturer 
projections, assuming equi-proportional migration from all comparators (combina-
tions including lenalidomide, thalidomide, melphalan and dexamethasone), except 
bortezomib SQ, which is constant. Cost of treatment is combined with literature-
based estimates for the adult prevalence of MM (0.0018%), cases that are relapsed/ 
refractory (52%), and likelihood of treatment (100%) to estimate annual costs for the 
full population. Results: The cost of treating 270 incident patients under current 
market shares is estimated at $27,699,084 ($102,510/patient). Assuming a 20% market 
share adoption of generic bortezomib IV, annual costs would increase by 26.2% to 
$34,944,197 ($129,323/patient), driven by the increased utilization of bortezomib IV 
($20,155/patient) relative to other regimens and increases in administration ($4,562/
patient) and AE costs ($2,096/patient). ConClusions: Increased utilization of generic 
bortezomib IV is not likely to translate into cost savings for the Venezuelan public 
payer given increased drug, AE and administration costs. Another option for lowering 
costs may be to promote the use of newer treatment alternatives that provide both 
high efficacy and favorable AE and administration profiles.
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objeCtives: Cancer incidence has increased in last decades. Meanwhile, new and 
costly intravenous chemotherapy drugs (CT) are added to current treatment options. 
Cost of chemotherapy is not restricted to drugs themselves, and some of the equip-
ment used for infusion can impact the final value. CT can be administered on simple 
IV lines although some require the use of pumps infusion sets (PIS) both of which 
may be PVC free or photosensitive depending on the drug. Nonetheless, several 
cancer centers in Brazil adopt CT pump infusion as a rule, despite manufacturers 
instructions. We aim to assess the added cost of unnecessary PIS use during CT infu-
sion. Methods: In this cost-minimization study we compared 2 scenarios: use of PIS 
according to manufacturer recommendations or as a rule for all CT. Chemotherapy 
treatments for breast cancer (AC-T, AC-TH, TAC, FAC, CMF and FEC100), lung cancer 
(carboplatin/paclitaxel with and without bevacizumab, vinorelbine/cisplatin, cispl-
atin/paclitaxel and pemetrexed/cisplatin) and colon cancer (fluorouracil/leucovorin, 
FOLFIRI, FOLFOX, cetuximab/irinotecan) were listed from the Brazilian Society of 
Clinical Oncology (SBOC) manual. Minimum, mean and maximal costs for drugs and 
equipment were retrieved from the official price list (SIMPRO), daily cost of infusion 
and increment in cost were also calculated in Brazilian Reais (R$). Results: Fifteen 
CT combinations were evaluated (6 for breast, 5 for colon and 4 for lung cancer). For 
breast cancer, the mean incremental cost per day of infusion with PIS varied from 
R$ 994.35 to R$ 1,839.54, depending on the chemotherapy scheme used. For lung 
cancer these values varied from R$ 356.34 a R$ 1,201.53 and for colon cancer treat-
ment the incremental cost was R$ 1,226.36. ConClusions: Although medications 
are the main source of expense in cancer treatment, unnecessary use of PIS can 
add considerable costs to chemotherapy and correct use according to manufacturer 
recommendation should be reinforced.
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The clinical benefit of stapled anastomosis creation of right colon resection surgery 
is expected to be accompanied by a strong potential economic benefit – as estimated 
for hospitals in Brazil.
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objeCtivos: estimar el costo por año de vida y años de vida ajustados por cali-
dad en pacientes con carcinoma basocelular localmente avanzado, tratados con 
vismodegib frente a tratarlos con radioterapia secundaria. MetodologíAs: se 
diseñó un modelo de Markov, con un horizonte temporal hasta la muerte, bajo 
ciclos semanales, que simula la historia natural de pacientes adultos con carci-
noma basocelular localmente avanzado, inapropiados para cirugía. Se utilizaron 
tres estados de salud: libres de progresión, progresión y muerte; utilizando réplicas 
de curvas de eventos de Kaplan-Meier, tanto para progresión como para sobrevida. 
Las probabilidades requeridas para la estimación del modelo fueron estimadas de 
los estudios ERIVANCE y STEVIE. Como desenlaces se utilizaron los años de vida 
ajustados por calidad y costos totales. Los costos de servicios fueron extraídos de 
bases de datos venezolanas, mientras que los de medicamentos fueron estimados 
con fuente del Ministerio del Poder Popular para la Salud. Además, se utilizó una tasa 
de descuento del 5% para costos y resultados. Por último, se realizó un análisis de 
sensibilidad tipo Montecarlo. ResultAdos: los años de vida, los años ajustados por 
calidad y el costo medio (en bolívares fuertes) de un paciente localmente avanzado, 
tratado con vismodegib fue de 6,55, 4,77 y $1.210.554 respectivamente, mientras 
que con radioterapia fue de 6,44, 4,45 y $628.908. Por ende, vismodegib tiene una 
mejor eficacia, lo cual se refleja en más del 86 % de las iteraciones en el análisis 
de sensibilidad. ConClusiones: vismodegib es dominante frente a radioterapia 
secundaria en eficacia, bajo el desenlace de años de vida ajustados por calidad. 
Su costo medio de uso anual es de $184.636, lo cual representa un impacto bajo, 
dada una prevalencia baja de 3,3 por 100.000 y solo del 5% en estadios avanzados.
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objeCtives: Multiple Myeloma (MM) is a hematological malignancy characterized 
by skeletal destruction, renal failure, anemia and hypercalcemia. Only 4 to 5% of 
the patients experience a survival of more than 10 years. The incidence reported 
worldwide was 114,251 new cases per year, with 1.5 cases per 100,000 residents. 
Given its low incidence, MM is considered orphan disease. The objective of the study 
is to estimate the budget impact to the Mexican public healthcare system when 
introducing Carfilzomib in the treatment of patients with refractory and relapsed 
MM who have received at least two previous treatments, including bortezomib and 
an immunomodulating agent. Methods: A budget impact analysis was conducted 
using a 3 health states Markov model (progression-free, post-progression and death) 
with monthly cycle length. The budget impact of Carfilzomib was compared to the 
current standard treatment in Mexico (high-dose dexamethasone), while low-dose 
dexamethasone was assumed after progression, according to Mexican KOLs advice. 
The eligible population was based on the incidence rate (3/100,000) for MM in Mexico 
and an estimate of the percentage of relapsed and refractory patients from the 
literature. Only direct medical costs were accounted for drugs, procedures, labora-
tory tests and adverse events management. Costs were expressed in US dollars 
(Exchange rate $15.16/USD) Results: After introducing Carfilzomib, incremental 
budget impact in the first 5 years wasestimated to have an average budget increase 
of .0033%. ConClusions: Assuming an increasing uptake of 5% per year, introduc-
ing Carfilzomib to the Mexican public healthcare system would on average increase 
budget by 0.0033%, being affordable in terms of funding and representing an effec-
tive and safe new therapeutic option for patients with relapsed and refractory MM.
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objeCtives: To conduct an exploratory analysis on the budgetary impact of migra-
tion from bortezomib IV to bortezomib SQ for the treatment of adults with relapsed/
refractory MM in Mexico. Methods: A budget impact model was developed using 
Microsoft Excel 2007® from the Mexican public payer perspective. Interviews with 
three clinicians (IMSS, INCAN, ISSSTE) currently treating relapsed/refractory MM 
patients were used to derive inputs for market shares, market basket compara-
tors, grade 3 and 4 adverse event (AE) management (anemia, thrombocytopenia, 
peripheral neuropathy, neutropenia, fatigue, pneumonia and infection) and practice 
patterns for drug administration. Treatment dosing and AE rates were based on a 
clinical trial comparing bortezomib SQ and bortezomib IV. Unit costs for healthcare 
resources and drugs reflect published IMSS rates (2015 Mexican pesos). Cost of 
treatment is combined with literature-based estimates for the adult prevalence 
of MM (0.0018%), population covered by public institutions (39%), cases that are 
relapsed/refractory (52%), and likelihood of bortezomib IV treatment (10%) to esti-
mate annual costs for this population. Results: The annual per-patient treatment 
cost for bortezomib IV was $653,136, including $495,486 in drug costs, $148,864 in 
